Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Urinary Bladder Neoplasms 2 Breast Neoplasms 2 Wilms Tumor 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neuroblastoma 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Neoplasm Metastasis 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lung Neoplasms 1 Hodgkin Disease 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Carboplatin 106 Pemetrexed 74 Paclitaxel 58 Cisplatin 52 Erlotinib Hydrochloride 51 Radiotherapy 49 Docetaxel 43 Gemcitabine 41 Bevacizumab 41 pembrolizumab 30 Nivolumab 25 Radiosurgery 21 Etoposide 20 durvalumab 13 Cetuximab 13 Specimen Handling 12 Ipilimumab 12 Magnetic Resonance Spectroscopy 11 Gefitinib 11 Vinorelbine 10 Taxes 10 Radiation 10 Albumin-Bound Paclitaxel 10 osimertinib 9 Biopsy 9 vandetanib 8 Topotecan 7 Platinum 7 Irinotecan 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lung Neoplasms × Genistein × Clear all

NCT02567799 2024-01-25

NSCLC

Humanetics Corporation

Phase 1/2 Completed

21 enrolled 32 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡